A Phase 1b/2 Study of AMG 655 in Combination With Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects With Metastatic Colorectal Cancer

Inclusion Criteria:

- Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or
rectum.

- Subjects with measurable or unmeasurable disease

- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1

- Men or women at least 18 years of age

- Adequate hematologic, renal, hepatic and coagulation function

Exclusion Criteria:

- History or known presence of central nervous system (CNS) metastases

- Prior chemotherapy or other systemic therapy for advanced or metastatic CRC

- Any investigational agent or therapy for advanced or metastatic CRC

- Clinically significant cardiac disease

- Clinically significant peripheral neuropathy

- Active inflammatory bowel disease

- Recent gastrointestinal ulcer or hemorrhage

- Recent arterial thrombotic event or pulmonary embolus

- Recent history of clinically significant bleeding, bleeding diathesis, or
coagulopathy

- Recent major surgical procedure or not yet recovered from major surgery